Core Points - BriaCell Therapeutics Corp. announced a public offering of 3,066,666 units at a price of $4.50 per unit, aiming for gross proceeds of approximately $13.8 million [1][2] - Each unit consists of one common share (or Pre-Funded Warrant) and one Warrant, with the Warrants approved for listing on the Nasdaq Capital Market under the symbol "BCTXZ" [1] - The offering is expected to close on April 28, 2025, subject to customary closing conditions [2] - The net proceeds will be used for working capital, general corporate purposes, and advancing business objectives [3] - A registration statement related to the securities was filed with the SEC and became effective on April 24, 2025 [4] Company Information - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [6]

(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patientTreatment well-tolerated and patient remains on study with stable disease elsewhereSustained clinical response supports Bria-OTS personalized, off-the-shelf immunotherapy approach in Phase 1/2a metastatic breast cancer study PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("Bri ...

PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3 at McCormick Place, Chicago, IL. The details ...

Over 75 patients enrolled in BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer (MBC)54 clinical sites across 15 states currently enrolling patients including Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer and Bood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center PHILADELPHIA and VAN ...

Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY® (sacituzumab govitecan-hziy) in similar heavily pre-treated patientsSurvival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY® No Bria-IMT related discontinuations reported to date PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025 (GLOBE NEWSWIRE) -- ...

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpointHighly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer target for drugs both effecting cancer cells and blocking immune checkpoint activityBriaPro expects to advance anti-B7-H3 antibodies into development of proprietary antibody-drug conjugates, T cell engagers, and targeted immune checkpoint inhibitors with potential applications in multiple cancer indicationsBriaPro ha ...

Core Insights - BriaCell Therapeutics Corp. will present three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting from April 25th to 30th in Chicago, IL [1][2] Group 1: Poster Presentations - Poster 1: Title is "Bria-ABC1 vs physician choice in late-stage MBC; early biomarker correlates of the randomized registration trial," scheduled for April 30, 2025, from 9:00 AM to 12:00 PM CST [2] - Poster 2: Title is "Survival outcomes in a randomized phase 2 of Bria-IMT: An allogeneic whole cell cancer vaccine," scheduled for April 28, 2025, from 2:00 PM to 5:00 PM CST [2] - Poster 3: Title is "Bria-OTS+: A versatile therapeutic platform for inducing anti-cancer immunity," scheduled for April 28, 2025, from 2:00 PM to 5:00 PM CST [2] Group 2: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [3]

The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer The pivotal Phase 3 study is currently under Fast Track Designation with the Food and Drug Administration (FDA) PHILADELPHIA and VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage ...

Clinical Trials and Research - BriaCell Therapeutics is advancing its Bria-IMT™ targeted immunotherapy in a pivotal Phase 3 study for metastatic breast cancer, currently under Fast Track Designation by the U.S. FDA[90]. - The Phase 2 study of Bria-IMT™ reported a median overall survival (OS) of 15.6 months, significantly higher than the 5.9-9.8 months reported for similar patients in the literature[93]. - The ongoing Phase 3 study has 35 clinical sites active and enrolling patients, with interim data analysis planned after 144 events (deaths) occur[99]. - In the Phase 2 study, patients treated with the Bria-IMT™ regimen had a one-year survival rate of 55%, exceeding the current standard of care[100]. - BriaCell received positive feedback from the FDA for its Pre-IND meeting regarding Bria-PROS+™ in prostate cancer, paving the way for a Phase 1/2 study[93]. - The FDA authorized an expanded access policy for Bria-IMT™ to provide treatment to metastatic breast cancer patients beyond the clinical trial scope[95]. - The Bria-OTS™ Phase 1/2a trial costs totaled $65,608 for the three-month period ended January 31, 2025, reflecting the trial's initiation in August 2024[120]. - The company remains committed to advancing the pivotal Phase 3 study of Bria-IMT™ in advanced breast cancer[131]. Financial Performance - For the three-month period ended January 31, 2025, the net loss attributable to BriaCell was $6,291,420, a decrease from $11,294,603 in the same period of 2024, reflecting a reduction in research, development, and clinical trial expenses[123]. - Total research, development, and clinical trial costs for the three months ended January 31, 2025, were $5,684,777, down from $8,257,455 in 2024, primarily due to lower clinical trial costs[117]. - The Bria-IMT™ Pivotal Phase 3 study costs increased to $3,642,650 in the three months ended January 31, 2025, compared to $2,519,420 in 2024, indicating intensified efforts in patient recruitment and trial execution[119]. - For the six-month period ended January 31, 2025, total research, development, and clinical trial costs were $9,350,118, significantly lower than $15,114,712 in 2024, driven by reduced clinical trial expenses[127]. - General and administrative expenses for the three-month period ended January 31, 2025, were $1,484,666, a slight decrease from $1,571,991 in 2024, attributed to operational efficiencies[121]. - Financial income for the three-month period ended January 31, 2025, was $67,358, down from $81,628 in 2024, primarily due to lower interest income[122]. - The change in fair value of the warrant liability resulted in a gain of $806,841 in the three-month period ended January 31, 2025, compared to a loss of $1,567,747 in 2024, contributing to improved financial results[123]. - The company reported a net loss per share attributable to BriaCell of $2.33 for the three-month period ended January 31, 2025, compared to $10.64 in 2024[114]. - For the six-month period ended January 31, 2025, the company reported a loss of $12,167,104, an increase from the loss of $5,375,038 in the same period of 2024[134]. - General and administrative expenses decreased to $2,972,157 for the six-month period ended January 31, 2025, compared to $3,217,762 for the same period in 2024, reflecting operational efficiencies[132]. - Financial income decreased to $79,072 for the six-month period ended January 31, 2025, down from $261,450 in 2024, primarily due to lower interest income[133]. - The accumulated deficit increased to $97,537,292 as of January 31, 2025, from $85,443,697 as of July 31, 2024[136]. - The company had total assets of $9,363,567 as of January 31, 2025, compared to $5,872,261 as of July 31, 2024, indicating improved financial position[136]. - The company achieved a positive working capital balance of $1,931,735 as of January 31, 2025, a significant improvement from a negative balance of $3,807,303 as of July 31, 2024[136]. - Cash gained in financing activities for the period ended January 31, 2025, was $17,176,863, compared to nil for the same period in 2024[140]. - The company’s net cash used in operating activities was $12,875,298 for the period ended January 31, 2025, compared to $15,006,564 for the same period in 2024[139]. Capital Raising Activities - BriaCell closed an $8.5 million offering for 821,666 common shares at $10.35 per share, intended for working capital and business objectives[94]. - The company closed a $5 million offering for 341,900 common shares and warrants, with gross proceeds intended for working capital and business advancement[98]. - The company closed a public offering on February 5, 2025, raising approximately $3.05 million from the sale of 762,500 common shares at a price of $4.00 per share[112]. Corporate Governance - The board approved a consolidation of common shares on a 1-for-15 basis to comply with Nasdaq listing requirements, effective January 29, 2025[110].

The price trend for BRIACELL THERAP (BCTX) has been bearish lately and the stock has lost 28.2% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that ...